DIANA COZMA: Open Payments
NPI 1578860672 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,063 in 33 payments from 7 companies in 2025. Trend: 2023 $380 · 2024 $762 · 2025 $1,063
Food & beverage: $1,063
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $352 |
| Teva Pharmaceuticals USA, Inc. | 7 | $206 |
| Otsuka America Pharmaceutical, Inc. | 2 | $144 |
| E.R. Squibb & Sons, L.L.C. | 2 | $126 |
| Vanda Pharmaceuticals Inc. | 3 | $81 |
| Janssen Pharmaceuticals, Inc | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $74 |
Products named: INGREZZA, UZEDY, ABILIFY MAINTENA, COBENFY, FANAPT, INVEGA SUSTENNA, CAPLYTA, AUSTEDO XR.
Industry payments across PA — which companies pay providers there.
